SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in

Peptide rules

Peptide rules by compound and jurisdiction

Scriptura reads federal law and each state's practice rules for select peptides and turns them into one clear view. Sources include FDA, DEA, USP, and each state pharmacy and medical board. Every rule on this site is traceable to the public government record.

This is decision support for prescribing clinicians. It is not legal advice, not FDA guidance, and not a device.

Scriptura flags, alerts, and informs. The prescribing clinician makes every decision.

Compounds covered today

5 compounds shown here. Additional clinician reviewed compounds are covered in the private clinician tool.

  • CJC-1295 No-DAC

    Growth hormone releasing peptide. Used in clinical research to raise the body's own growth hormone in adults, without a long-acting tag.

    Federal posture: Not FDA approved, compounding not eligible under 503A today. Shown as under active review in 52 of 52 US jurisdictions. Open the compound page to see which.

  • Ipamorelin

    Growth hormone releasing peptide. Used in clinical research to raise the body's own growth hormone with less effect on cortisol and prolactin.

    Federal posture: Not FDA approved, compounding not eligible under 503A today. Shown as under active review in 52 of 52 US jurisdictions. Open the compound page to see which.

  • Semaglutide

    GLP-1 medicine. FDA approved to help control blood sugar in adults with type 2 diabetes and to help with weight loss.

    Federal posture: FDA approved for a specific indication. Shown as no compound specific state restriction in 52 of 52 US jurisdictions. Open the compound page to see which.

  • Tesamorelin

    Growth hormone releasing peptide. FDA approved for HIV-related belly fat and studied for age-related decline in growth hormone.

    Federal posture: FDA approved for a specific indication. Shown as no compound specific state restriction in 52 of 52 US jurisdictions. Open the compound page to see which.

  • Tirzepatide

    Dual GIP and GLP-1 medicine. FDA approved to help control blood sugar in adults with type 2 diabetes and to help with weight loss.

    Federal posture: FDA approved for a specific indication. Shown as no compound specific state restriction in 52 of 52 US jurisdictions. Open the compound page to see which.

Read the federal timeline for peptide compounding, July 2026.

Get Scriptura in your clinic

See how Scriptura pulls federal, state, and clinical sources into one reviewed view for prescribing clinicians. Book a live walkthrough, or get short updates when the rules move.

Reviewed by Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health.

Peptide rules by compound and jurisdiction | Scriptura Health